Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Tumors 1Hematologic Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Homoharringtonine × Clear all
NCT01844869 2015-01-30

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00675350 2014-05-12

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
12 enrolled

Hematologic Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡